한글목차

루센티스(라니비주맙) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 374만 달러에서 2026년에는 396만 달러에 이르고, CAGR 5.7%로 성장할 전망입니다. 지난 수년간의 성장에는 노화성 황반변성에서 임상적 성공, 당뇨병성 망막증 환자 증가, 고령화, 안과 의사들의 채용 확대, 안과 의료 분야에서의 규제 당국의 승인 등이 주요 요인으로 꼽힙니다.

루센티스(라니비주맙) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 487만 달러에 이르고, CAGR은 5.4%를 나타낼 전망입니다. 예측 기간 동안의 성장은 망막 질환의 유병률 증가, 안과 의료 서비스 접근성 확대, 바이오시밀러 경쟁 확대, 조기 진단에 대한 인식 개선, 주사제 투여 기술의 발전 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 항VEGF 요법의 지속적인 사용, 망막혈관질환 치료 증가, 유리체내 주사 선호도 증가, 안과 전문 클리닉의 확대, 시력 유지에 대한 관심 증가 등을 꼽을 수 있습니다.

안과 관련 질환의 유병률 증가는 향후 몇 년 동안 루센티스(라니비주맙) 시장의 성장을 견인할 것으로 예측됩니다. 눈 관련 질환이란 눈에 영향을 미쳐 정상적인 기능을 손상시키는 다양한 병태를 말합니다. 이러한 질환 증가는 노화, 유전적 소인, 흡연, 부적절한 식습관 등 건강에 해로운 생활습관, 장시간의 햇빛 노출, 과도한 디지털 화면 사용 등 환경적 요인에 기인합니다. 루센티스는 혈관내피성장인자(VEGF)를 억제하여 작용합니다. VEGF는 망막에서 비정상적인 혈관 증식 및 누출을 유발하는 단백질로, 노화성 황반변성(AMD), 당뇨성 황반부종(DME) 등의 질환의 주요 원인으로 작용합니다. 예를 들어, 미국 정부기관인 국립안연구소(NEI)는 2024년, 2030년까지 220만 명의 미국인이 실명할 것으로 예측했습니다. 따라서 안질환의 유병률 증가가 루센티스(라니비주맙) 시장 확대를 견인하고 있습니다.

헬스케어 지출 증가도 루센티스(라니비주맙) 시장의 성장을 뒷받침할 것으로 예측됩니다. 헬스케어 지출은 개인, 정부, 민간 보험사 및 기타 조직이 의료 서비스 및 제품에 할당하는 총 자금을 의미합니다. 이러한 증가는 고령화, 의료기술의 발전, 만성질환 증가, 의료서비스에 대한 수요 증가에 의해 촉진되고 있습니다. 의료비 지출 증가는 루센티스(라니비주맙)가 노화성 황반변성(AMD) 및 당뇨병성 황반부종(DME)과 같은 망막 질환 치료에 있어 루센티스의 보급을 돕고, 의료 시스템이 루센티스의 보험 적용, 상환 및 유통에 자원을 배분할 수 있도록 함으로써 루센티스의 접근성 및 가용성을 향상시킬 수 있습니다. 이는 궁극적으로 환자의 치료 결과를 개선하고 시력 상실의 장기적인 부담을 줄일 수 있습니다. 예를 들어, 2024년 5월 영국 정부 기관인 국가통계청이 발표한 바에 따르면, 영국의 의료비 지출은 2022년부터 2023년까지 5.6% 증가했다고 합니다. 이는 2022년 0.9% 증가에 비해 큰 폭의 성장세를 보이고 있습니다. 2023년 영국의 총 의료비 지출은 약 3,176억 3,000만 달러(2,920억 파운드)에 달할 것으로 예측됩니다. 이에 따라 의료비 증가가 루센티스(라니비주맙) 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

Lucentis (ranibizumab) is a prescription drug used to treat a range of eye conditions involving abnormal blood vessel growth in the retina. It is a recombinant monoclonal antibody fragment that works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for the formation of abnormal blood vessels.

The main forms of Lucentis (ranibizumab) available in the market are single-use prefilled syringes and single-use glass vials. A single-use prefilled syringe is a medical device containing a pre-measured dose of medication, ready for immediate use. Its applications include age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, myopic choroidal neovascularization, and uveitis. Key end-users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

Tariffs have influenced the Lucentis market by increasing costs for imported biologic substances, prefilled syringe components, and cold chain logistics. These impacts are more visible in regions dependent on imported ophthalmic biologics, particularly asia pacific and latin america. Hospital and clinic procurement costs have increased, affecting treatment affordability. However, tariffs have driven local packaging and distribution partnerships. This supports supply continuity and improves regional market resilience.

The lucentis (ranibizumab) market research report is one of a series of new reports from The Business Research Company that provides lucentis (ranibizumab) market statistics, including lucentis (ranibizumab) industry global market size, regional shares, competitors with a lucentis (ranibizumab) market share, detailed lucentis (ranibizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the lucentis (ranibizumab) industry. This lucentis (ranibizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lucentis (ranibizumab) market size has grown strongly in recent years. It will grow from $3.74 million in 2025 to $3.96 million in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to clinical success in macular degeneration, rising diabetic retinopathy cases, aging population, ophthalmologist adoption, regulatory approvals in eye care.

The lucentis (ranibizumab) market size is expected to see strong growth in the next few years. It will grow to $4.87 million in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growth in retinal disease prevalence, increasing access to eye care services, expansion of biosimilar competition, rising awareness of early diagnosis, technological advances in injection delivery. Major trends in the forecast period include sustained use of anti vegf therapies, rising treatment of retinal vascular disorders, growing preference for intravitreal injections, expansion of ophthalmology specialty clinics, increased focus on vision preservation.

The rising prevalence of eye-related disorders is expected to drive the growth of the Lucentis (ranibizumab) market in the coming years. Eye-related disorders encompass a variety of conditions that affect the eyes and impair their proper functioning. The increasing occurrence of these disorders is attributed to aging, genetic predisposition, unhealthy lifestyle choices such as smoking and poor diet, and environmental factors like prolonged sun exposure or extended digital screen use. Lucentis acts by inhibiting vascular endothelial growth factor (VEGF), a protein that causes abnormal blood vessel growth and leakage in the retina, which is a major contributor to conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). For example, in 2024, the National Eye Institute, a US government agency, projected that 2.2 million Americans will be blind by 2030. Therefore, the growing prevalence of eye-related disorders is fueling the expansion of the Lucentis (ranibizumab) market.

The increase in healthcare spending is also expected to support the growth of the Lucentis (ranibizumab) market. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other organizations for healthcare services and products. This increase is driven by an aging population, advancements in medical technologies, rising prevalence of chronic diseases, and higher demand for healthcare services. Greater healthcare spending enhances the accessibility and availability of Lucentis (ranibizumab) by supporting its widespread use in treating retinal conditions like AMD and DME, ensuring healthcare systems can allocate resources for its coverage, reimbursement, and distribution, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to 0.9% growth in 2022. The total UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. As a result, rising healthcare spending is driving the growth of the Lucentis (ranibizumab) market.

Key players in the Lucentis (ranibizumab) market are focusing on developing biosimilars to offer more affordable alternatives to the original branded product. Biosimilars are biologic medicines that are highly similar to an already approved reference biologic in structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biotechnology company, launched their biosimilar version of Lucentis (ranibizumab), called FYB201, in Canada and Switzerland. Health Canada granted marketing authorization under the name Ranopto, while Swiss Medic approved it as Ranivisio. The approval and launch of FYB201 aim to provide more affordable treatment options for patients with retinal diseases. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes abnormal blood vessel growth in the retina, which can cause swelling, leakage, and vision impairment.

Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG

North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lucentis (ranibizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The lucentis (ranibizumab) market consists of sales of lucentis intravitreal injection and lucentis for biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lucentis (Ranibizumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses lucentis (ranibizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lucentis (ranibizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lucentis (ranibizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Single-use Prefilled Syringe; Single-use Glass Vial
• 2) By Application: Age-related Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Myopic Choroidal Neovascularization; Uveitis
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Companies Mentioned: F.Hoffmann-La Roche Ltd; Novartis AG
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Lucentis (Ranibizumab) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Lucentis (Ranibizumab) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Lucentis (Ranibizumab) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Lucentis (Ranibizumab) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Sustained Use Of Anti Vegf Therapies
  • 4.2.2 Rising Treatment Of Retinal Vascular Disorders
  • 4.2.3 Growing Preference For Intravitreal Injections
  • 4.2.4 Expansion Of Ophthalmology Specialty Clinics
  • 4.2.5 Increased Focus On Vision Preservation

5. Lucentis (Ranibizumab) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Ophthalmology Clinics
• 5.3 Ambulatory Surgical Centers
• 5.4 Eye Care Specialty Centers
• 5.5 Research Hospitals

6. Lucentis (Ranibizumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Lucentis (Ranibizumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Lucentis (Ranibizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Lucentis (Ranibizumab) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Lucentis (Ranibizumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Lucentis (Ranibizumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Lucentis (Ranibizumab) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Lucentis (Ranibizumab) Market Segmentation

• 9.1. Global Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single-use Prefilled Syringe, Single-use Glass Vial
• 9.2. Global Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Uveitis
• 9.3. Global Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

10. Lucentis (Ranibizumab) Market Regional And Country Analysis

• 10.1. Global Lucentis (Ranibizumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Lucentis (Ranibizumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Lucentis (Ranibizumab) Market

• 11.1. Asia-Pacific Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Lucentis (Ranibizumab) Market

• 12.1. China Lucentis (Ranibizumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Lucentis (Ranibizumab) Market

• 13.1. India Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Lucentis (Ranibizumab) Market

• 14.1. Japan Lucentis (Ranibizumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Lucentis (Ranibizumab) Market

• 15.1. Australia Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Lucentis (Ranibizumab) Market

• 16.1. South Korea Lucentis (Ranibizumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Lucentis (Ranibizumab) Market

• 17.1. Western Europe Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Lucentis (Ranibizumab) Market

• 18.1. UK Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Lucentis (Ranibizumab) Market

• 19.1. Germany Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Lucentis (Ranibizumab) Market

• 20.1. France Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Lucentis (Ranibizumab) Market

• 21.1. Eastern Europe Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Lucentis (Ranibizumab) Market

• 22.1. North America Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Lucentis (Ranibizumab) Market

• 23.1. USA Lucentis (Ranibizumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Lucentis (Ranibizumab) Market

• 24.1. Canada Lucentis (Ranibizumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Lucentis (Ranibizumab) Market

• 25.1. South America Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Lucentis (Ranibizumab) Market

• 26.1. Middle East Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Lucentis (Ranibizumab) Market

• 27.1. Africa Lucentis (Ranibizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Lucentis (Ranibizumab) Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Lucentis (Ranibizumab) Market Regulatory and Investment Landscape

29. Lucentis (Ranibizumab) Market Competitive Landscape And Company Profiles

• 29.1. Lucentis (Ranibizumab) Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Lucentis (Ranibizumab) Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Lucentis (Ranibizumab) Market Company Profiles
  • 29.3.1. F.Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30. Global Lucentis (Ranibizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Lucentis (Ranibizumab) Market

32. Lucentis (Ranibizumab) Market High Potential Countries, Segments and Strategies

• 32.1 Lucentis (Ranibizumab) Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Lucentis (Ranibizumab) Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Lucentis (Ranibizumab) Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer